Upstream Bio outlines Phase 3 plan for verekitug
Upstream Bio announced pivotal Phase 3 plans for verekitug, including a 400mg subcutaneous dose every 12 weeks and two placebo-controlled trials totaling about 1,500 patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Upstream Bio outlines Phase 3 plans for verekitug in asthma and CRSwNP
Upstream Bio says it will study 400 mg verekitug every 12 weeks versus placebo in severe asthma and CRSwNP, using one pivotal Phase 3 trial per indication after FDA discussions.